Yamel Cardona Gloria

Yamel Cardona Gloria

Auto-generated profile, based on publicly available information

Yamel Cardona Gloria

Department of Innate Immunity, Institute of Immunology, University of Tuebingen, Tuebingen, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ZBZsófia Agnes Bittner
Zsófia Agnes Bittner
XLXiao Liu
Xiao Liu
MTMaria Mateo Tortola
Maria Mateo Tortola
ATANA TAPIA-ABELLAN
ANA TAPIA-ABELLAN
SSSangeetha Shankar
Sangeetha Shankar
AWAlexander Weber
Alexander Weber
Activity of the NLRP3 inflammasome, a critical mediator of inflammation, is controlled by accessory proteins, posttranslational modifications, cellular localization, and oligomerization. How these factors relate is unclear. We show that a well-established drug target, Bruton’s tyrosine kinase (BTK), affects several levels of NLRP3 regulation. BTK directly interacts with NLRP3 in immune cells and phosphorylates four conserved tyrosine residues upon inflammasome activation, in vitro and in vivo. Furthermore, BTK promotes NLRP3 relocalization, oligomerization, ASC polymerization, and full inflammasome assembly, probably by charge neutralization, upon modification of a polybasic linker known to direct NLRP3 Golgi association and inflammasome nucleation. As NLRP3 tyrosine modification by BTK also positively regulates IL-1β release, we propose BTK as a multifunctional positive regulator of NLRP3 regulation and BTK phosphorylation of NLRP3 as a novel and therapeutically tractable step in the control of inflammation.

7 February 2024 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Open access
ASAthanasios Saratzis
Athanasios Saratzis
GTGiovanni B. Torsello
Giovanni B. Torsello
YCYamel Cardona-Gloria
Yamel Cardona-Gloria
IHIsabelle Van Herzeele
Isabelle Van Herzeele
SMSarah J. Messeder
Sarah J. Messeder
NTNicola Troisi
Nicola Troisi
To report the cost of target lesion revascularisation procedures (TLR) for femoropopliteal peripheral artery disease (PAD) following stenting, from a healthcare payer's perspective. European multicentre study involving consecutive patients requiring femoropopliteal TLR (January 2017 - December 2021). The primary outcome was overall cost associated with a TLR procedure from presentation to discharge (euros). Exact costs per constituent, clinical characteristics, and early outcomes were reported. This study included 482 TLR procedures (retrospectively, 13 hospitals, six countries): 56% were female, mean age was 75 ± 2 years, 61% were Rutherford class 5 or 6, 67% had Tosaka class 3 disease, and 16% had common femoral or iliac involvement. A total of 52% were hybrid procedures and 6% involved only open surgery. Technical success was 70%, 30 day mortality was 1%, and the 30 day major amputation rate was 4%. Most costs were due to operating time during the TLR (healthcare professionals' salaries, indirect/estate costs), with a mean of: €21 917 ± 2 110 for all procedures; €23 337 ± 8 920 for open procedures; €12 903 ± 3 108 for endovascular procedures; and €22 806 ± 3 977 for hybrid procedures. In a regression analysis, procedure duration per hour was the main parameter associated with higher overall TLR costs (coefficient, 2.77; standard error, 0.88; p < .001). The mean cost per operating minute of TLR (indirect, estate costs, all salaried staff present included) was €177 and the mean cost per night stay in hospital (outside intensive care unit) was €356. The mean cost per overnight intensive care unit stay (minimum of 8 hours per night) was €1 193. The main driver of the considerable actuarial periprocedural costs associated with femoropopliteal TLR was procedural time.

25 January 2023 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
Paolo SpathPaolo Spath
Paolo Spath
YCYamel Cardona-Gloria
Yamel Cardona-Gloria
GTGiovanni Torsello
Giovanni Torsello
EGEnrico Gallitto
Enrico Gallitto
TÖTugce Öz
Tugce Öz
NTNikolaos Tsilimparis
Nikolaos Tsilimparis

8 November 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
ASAude Sylvain
Aude Sylvain
NSNatacha Stoehr
Natacha Stoehr
FMFupeng Ma
Fupeng Ma
ACArtiom Cernijenko
Artiom Cernijenko
MSMartin Schröder
Martin Schröder
ZBZuni I. Bassi
Zuni I. Bassi
Summary: The NLRP3 (NACHT-, leucine-rich repeat [LRR]- and pyrin domain [PYD]- containing protein 3) inflammasome is a cytoplasmic signaling complex that promotes inflammation in response to signals from infection and cellular damage. Increased activation of the NLRP3 inflammasome is linked to numerous diseases including gout, osteoarthritis, cardiovascular disease, neuroinflammatory diseases and cancer, which has prompted the search for therapeutics that can inhibit the NLRP3 pathway. Recent work suggested that NIMA-related kinase 7 (NEK7) may be required for proper assembly and activation of the NLRP3 inflammasome independent of its kinase activity, and that hence reduction of NEK7 protein levels may block NLRP3 activation. Since NEK7 contains a glycine beta hairpin loop structural degron found in many targets of cereblon (CRBN) molecular glue degraders, we used this strategy to degrade NEK7 and inhibit the NLRP3 inflammasome. We identified NK7-902, a CRBN glue degrader of NEK7. NK7-902 potently and selectively degraded NEK7 in human primary monocytes, peripheral blood mononuclear cells (PBMCs) and whole blood. Unexpectedly, full NEK7 degradation led to only partial blockade of NLRP3-dependent interleukin-1β (IL-1β) release in these cells under different stimulation conditions, with the extent of IL-1β inhibition varying greatly across donors. Unlike most CRBN glue degraders, NK7-902 degraded NEK7 in mouse cells and efficiently inhibited NLRP3-dependent IL-1β release in a mouse cryopyrin-associated syndrome (CAPS) model. By contrast, oral administration of NK7-902 in non-human primates led to profound and long lasting NEK7 degradation but only transiently blocked IL-1β production in blood. Collectively, our data suggest that NEK7 is involved but may not be strictly required for NLRP3 activation in primates and humans. Highlights: Identification of NK7-902, a CRBN molecular glue degrader of NEK7 NK7-902 fully degrades NEK7 in human primary monocytes and whole blood but only partially inhibits NLRP3-dependent IL-1β production Unlike most CRBN glue degraders, NK7-902 shows activity in murine systems In vivo oral administration of NK7-902 in non-human primates leads to profound and long-lasting NEK7 degradation but only transiently blocks NLRP3 inflammasome activation

8 March 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SBShreya Bhattacharya
Shreya Bhattacharya
AMAlec Jacob Maupin
Alec Jacob Maupin
ASAnders Grønnegaard Schlosser
Anders Grønnegaard Schlosser
EFErnst-Martin Füchtbauer
Ernst-Martin Füchtbauer
YGYamel Cardona Gloria
Yamel Cardona Gloria
STSteven P Templeton
Steven P Templeton
Chitin, a polysaccharide, is ubiquitously found in nature and has been known to be an active immunogen in mammals, and interacts with Toll-like, mannose and glucan receptors, to induce cytokine and chemokine secretions. FIBCD1 is a tetrameric type II transmembrane endocytic vertebrate receptor that binds chitin, is found in human lung epithelium and modulates lung epithelial inflammatory responses to A. fumigatus cell wall polysaccharides. We previously reported the detrimental role of FIBCD1 in a murine model of pulmonary invasive aspergillosis. However, the effect that chitin and chitin-containing A. fumigatus conidia exerts on lung epithelium following exposure through FIBCD1 is not yet fully explored. Using both in vitro and in vivo strategies, we examined how lung and lung epithelial gene expression are modified after exposure to fungal conidia or chitin fragments in the presence or absence of FIBCD1. FIBCD1 expression was associated with a decrease in inflammatory cytokines with increasing size of chitin (dimer-oligomer). Thus, our results demonstrate that FIBCD1 expression modulates cytokine and chemokine expression in response to A. fumigatus conidia that is modified by the presence of chitin particles.